V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10004707 | 10002965 | 1.71 | 78.5 | Palliative (P) | 2017-05-01 | 2017-05-25 | Cyclophosphamide oral | 2 | y | 10542857 | VINORELBINE |
| 10004708 | 10002965 | 1.6 | 69.5 | Disease modification (D) | 2015-11-27 | 2015-11-28 | Temozolomide 150mg/m2 | 02 | N | 10542857 | PALBOCICLIB |
| 10004709 | 10002966 | 1.69 | 100.9 | Neo-adjuvant (N) | 2018-01-07 | 2018-01-07 | DABRAFENIB + TRAMETINIB | 2 | N | 10543189 | VINCRISTINE |
| 10004710 | 10002967 | null | 91.4 | Neo-adjuvant (N) | 2014-07-23 | 2014-07-29 | CARFILZOMIB + CYCLOPHOSPHAMIDE | null | N | 10543270 | CHLORAMBUCIL + RITUXIMAB |
| 10004711 | 10006699 | 1.69 | 63.2 | Palliative (P) | 2016-11-22 | 2016-11-23 | CYCLOPHOSPHAMIDE + LENALIDOMIDE | N | N | 10543310 | EVEROLIMUS |
| 10004712 | 10006699 | 1.82 | 103 | Palliative (P) | 2016-08-23 | 2016-08-23 | IRINOTECAN + MDG + PANITUMUMAB | 2 | N | 10543310 | RUXOLITINIB |
| 10004713 | 10002968 | null | null | Disease modification (D) | 2016-12-15 | 2016-12-21 | RUXOLITINIB | 01 | N | 10543551 | FEC + DOCETAXEL + TRASTUZUMAB |
| 10004714 | 10002968 | 0 | 81.7 | Curative (C) | 2017-08-22 | 2017-08-23 | RUXOLITINIB | 01 | N | 10543551 | IPILIMUMAB + NIVOLUMAB |
| 10004715 | 10002969 | null | 68.3 | Curative (C) | 2016-01-19 | 2016-01-23 | Capecitabine + Cisplatin + RT | N | N | 10543662 | CHLORAMBUCIL + ETOPOSIDE + LOMUSTINE |
| 10004716 | 10002970 | 1.72 | 70 | Palliative (P) | 2018-03-03 | 2018-03-26 | Gefitinib: Cycle 3 only (PAS) | 2 | N | 10543674 | CAPECITABINE + CARBOPLATIN |
| 10004717 | 10006701 | 1.64 | 71.8 | Palliative (P) | 2015-05-16 | 2015-05-21 | Bevacizumab + Capecitabine | 02 | N | 10543748 | CHLVPP |
| 10004718 | 10002971 | 1.69 | 69.1 | Curative (C) | 2018-05-15 | 2018-05-16 | R Chlorambucil | 2 | N | 10543799 | CARBOPLATIN + EPIRUBICIN + PACLITAXEL |
| 10004719 | 10002971 | 1.64 | 87 | Curative (C) | 2018-06-05 | 2018-06-11 | Busulfan Oral | 2 | N | 10543799 | MPV |
| 10004720 | 10002971 | 1.77 | 96 | Palliative (P) | 2017-02-27 | 2017-03-09 | RUXOLITINIB | N | N | 10543799 | ACELARATE TRIAL |
| 10004721 | 10002972 | 0 | 99.9 | Curative (C) | 2017-01-26 | 2017-01-26 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | N | N | 10543842 | CHLORAMBUCIL + OBINUTUZUMAB |
| 10004722 | 10002973 | null | 84.85 | Palliative (P) | 2016-01-10 | 2016-01-11 | VINCRISTINE | 02 | N | 10543844 | CYTARABINE |
| 10004723 | 10002974 | 1.66 | 51.8 | Palliative (P) | 2016-05-21 | 2016-05-22 | RUXOLITINIB | N | N | 10543909 | CETUXIMAB |
| 10004724 | 10006703 | 1.6 | null | Curative (C) | null | 2017-07-19 | Bendamustine +/- Prednisolone | 2 | null | 10543913 | PAZOPANIB |
| 10004725 | 10002975 | 1.79 | 57.4 | Palliative (P) | 2017-07-02 | 2017-07-14 | Bevacizumab 5mg/kg | N | N | 10543951 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10004726 | 10002976 | 1.73 | 85.9 | Curative (C) | 2017-04-11 | 2017-04-12 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 02 | N | 10543984 | MELPHALAN |
| 10004727 | 10002977 | 1.75 | 53.5 | Curative (C) | 2017-03-30 | 2017-03-30 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | N | 10544006 | BENDAMUSTINE |
| 10004728 | 10002978 | 1.68 | null | Palliative (P) | 2016-09-12 | 2016-09-13 | FLUOROURACIL + MITOMYCIN | 02 | N | 10544017 | SUNITINIB |
| 10004729 | 10002979 | 1.67 | 67.2 | Disease modification (D) | 2017-03-05 | 2017-03-27 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | 10544071 | R CODOX M |
| 10004730 | 10002979 | 1.77 | null | Adjuvant (A) | 2016-08-02 | 2016-08-09 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 02 | N | 10544071 | ERLOTINIB |
| 10004731 | 10002980 | 0 | 62 | null | 2017-01-15 | 2017-02-05 | AML 19 TRIAL | 2 | N | 10544134 | NOT MATCHED |
| 10004732 | 10002981 | null | 69 | Palliative (P) | 2015-05-26 | 2015-06-16 | Bortezomib + MELPHALAN | N | N | 10544187 | ENRICH TRIAL |
| 10004733 | 10002981 | 0 | 79.8 | Palliative (P) | 2013-11-09 | 2013-11-09 | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE | N | N | 10544187 | CHLORAMBUCIL + RITUXIMAB |
| 10004734 | 10002982 | 1.77 | null | Palliative (P) | null | 2017-04-25 | MPV (cycle 1-4) | N | N | 10544252 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10004735 | 10002982 | 1.78 | null | Palliative (P) | 2014-08-20 | 2014-08-20 | IPILIMUMAB + NIVOLUMAB | N | Y | 10544252 | MPV |
| 10004736 | 10002982 | null | 72.6 | Curative (C) | 2015-12-11 | 2015-12-04 | RUXOLITINIB | N | null | 10544252 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10004737 | 10002982 | 1.63 | 86.6 | Adjuvant (A) | 2017-07-21 | 2017-08-15 | Lenalidomide 10mg (Cycle 1 to 25) | N | N | 10544252 | MITOMYCIN |
| 10004738 | 10002983 | 1.79 | 107.2 | Disease modification (D) | 2016-09-09 | 2016-09-26 | DABRAFENIB + TRAMETINIB | N | N | 10544357 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 10004739 | 10002984 | 1.81 | 61 | Palliative (P) | 2015-06-17 | 2015-06-20 | Pazopanib | N | N | 10544405 | CHLVPP |
| 10004740 | 10002985 | null | 78 | null | 2016-06-16 | 2016-07-07 | BLEOMYCIN | null | null | 10544507 | CETUXIMAB + CISPLATIN + FU |
| 10004741 | 10002986 | 1.65 | 102 | Palliative (P) | 2018-05-26 | 2018-06-07 | IPILIMUMAB + NIVOLUMAB | Y | N | 10544566 | MPT |
| 10004742 | 10002987 | 1.65 | 56 | Curative (C) | 2017-05-25 | 2017-05-27 | Pemetrexed | 02 | N | 10544570 | VINORELBINE |
| 10004743 | 10002988 | 1.78 | 79.6 | Palliative (P) | 2016-02-15 | 2016-02-29 | CISPLATIN + FLUOROURACIL | N | N | 10544598 | CISPLATIN + FLUOROURACIL |
| 10004744 | 10002988 | 1.84 | 95 | Palliative (P) | 2016-02-26 | 2016-02-28 | ECarboX | N | N | 10544598 | CAPECITABINE + IRINOTECAN |
| 10004745 | 10008215 | null | null | Palliative (P) | 2016-07-17 | 2016-07-19 | Cisplatin +Fluorouracil (3 wk) | 2 | Y | 10544678 | CYCLOPHOSPHAMIDE + LENALIDOMIDE |
| 10004746 | 10002989 | 1.75 | 100.1 | Neo-adjuvant (N) | 2019-01-16 | 2019-01-20 | CISPLATIN + DOCETAXEL + FLUOROURACIL | 2 | null | 10544697 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10004747 | 10006708 | 1.71 | 63 | Adjuvant (A) | 2017-11-11 | 2017-11-16 | Cytarabine Low Dose | N | N | 10544783 | CARBO + FLUOROURACIL |
| 10004748 | 10002990 | 1.7 | 92.1 | Neo-adjuvant (N) | 2015-03-09 | 2015-03-15 | Ofatumumab Monthly | 02 | N | 10544806 | ECF |
| 10004749 | 10002991 | null | 71.7 | Palliative (P) | 2017-10-22 | 2017-11-05 | RCEOP | N | N | 10544882 | CARBO + FLUOROURACIL |
| 10004750 | 10002991 | 1.63 | 61.6 | Palliative (P) | 2015-06-25 | 2015-07-04 | AFATINIB | 1 | null | 10544882 | CYCLOPHOSPHAMIDE + DOCETAXEL + TRASTUZUMAB |
| 10004751 | 10002992 | null | 64 | Palliative (P) | 2018-04-13 | 2018-04-21 | CYTARABINE | 2 | N | 10544898 | SORAFENIB |
| 10004752 | 10002992 | 1.9 | 70 | Palliative (P) | 2016-11-22 | 2016-11-29 | CISPLATIN + FLUOROURACIL | 02 | Y | 10544898 | MITOMYCIN |
| 10004753 | 10002993 | null | 71 | null | 2015-11-03 | 2015-11-18 | Sorafenib | N | N | 10544975 | SORAFENIB |
| 10004754 | 10002994 | null | 70 | Curative (C) | 2017-02-25 | 2017-02-25 | DOXORUBICIN | 02 | N | 10545005 | IPILIMUMAB |
| 10004755 | 10002994 | 1.59 | 53 | Adjuvant (A) | 2018-03-12 | 2018-05-07 | BLEOMYCIN | 02 | N | 10545005 | VEMURAFENIB |
| 10004756 | 10002995 | 1.62 | 72.6 | Disease modification (D) | 2018-10-08 | 2018-10-08 | CARBOPLATIN + RT | 2 | N | 10545056 | FLUOROURACIL + MITOMYCIN |